Articles by Hellen Berger - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

  • Search
  • Suppliers
  • Careers

Enter a company or product name

Keyword Location
About Search
Articles by Hellen Berger

Hellen Berger


Hellen Berger is a business writer based in Sao Paulo, Brazil.

Articles
Pharma Industry Growth Slows in Brazil
November 1, 2014

The Brazilian economy is being impacted by internal and external factors, and forecast figures are being quickly revised downwards.

Economic Growth Stalls in Brazil
October 2, 2014

Brazil's pharmaceutical industry is optimistic, but is the pharmaceutical market growing steadily or showing signs of instability?

Brazil's Phytotherapic Drug Market and Regulation
July 2, 2014

Is there potential for growth in Brazil's phytotherapic drug market?

Global Instability Impacts Brazil's Pharma Market
May 2, 2014

How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?

Global Instability Affects the Pharma Market in Brazil
April 2, 2014

How badly is Brazil's pharmaceutical market suffering from the global instability of emerging markets?

Innovation and Market Growth in Brazil
January 2, 2014

Brazil is the first Latin American country to emerge as a global biopharmaceutical collaborator.

Report from Brazil
November 2, 2013

New regulation offers patients in Brazil greater access to experimental drugs.

Report from Brazil
September 2, 2013

Pharma eyes biologics production in Brazil as the government begins to recognize the potential of these drugs.

Report from Brazil
July 2, 2013

Brazil offers opportunities and challenges for global pharmaceutical companies.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
FindPharma Custom Search
Click here